The University of Auckland and Uniservices
LCT has partnered on three projects with UniServices, the commercialisation arm of the University of Auckland. These include the current projects targeting treatments for obesity and migraine.
Diatranz Otsuka Limited
LCT has licensed its DIABECELL technology to Diatranz Otsuka Limited (DOL) for a 5 percent royalty of any sales related to the use of this technology. DOL was initially formed as a 50/50 joint venture between LCT and Otsuka Pharmaceutical Factory (OPF).